Screener
Rigel Pharmaceuticals RIGL Discounts and allowances — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Product sales: | ||
| Gross product sales | $75,388 | $60,192 |
| Discounts and allowances | (20,465) | (16,642) |
| Total product sales, net | 54,923 | 43,550 |
| Contract revenues from collaborations: | ||
| Milestone revenue | — | 3,000 |
| Delivery of drug supplies, royalties and others | 3,895 | 6,783 |
| Total contract revenues from collaborations | 3,895 | 9,783 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's discounts and allowances — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported discounts and allowances — revenue recognized of -$20.47M in Q1 2026.
- How has Rigel Pharmaceuticals's discounts and allowances — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's discounts and allowances — revenue recognized decreased by 23.0% year-over-year, from -$16.64M to -$20.47M.
- What is the long-term trend for Rigel Pharmaceuticals's discounts and allowances — revenue recognized?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's discounts and allowances — revenue recognized has grown at a 43.9% compound annual growth rate (CAGR), from -$18.18M to -$77.98M.
- What does discounts and allowances — revenue recognized mean?
- This metric represents the total contra-revenue adjustments applied to gross product sales, including rebates, chargebacks, cash discounts, and returns. It reflects the financial impact of contractual obligations and market access agreements that reduce the net revenue realized from product sales. Monitoring this figure is essential for assessing the company's pricing power, the effectiveness of its commercial distribution strategy, and the underlying net realization rate of its pharmaceutical portfolio.
Ask your AI about Rigel Pharmaceuticals's discounts and allowances — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude